Sweden's SenzaGen Q4 GARD sales rise 13% on major US orders

SenzaGen AB

13/02/2026 06:39

Overview

Sweden non-animal testing firm's Q4 GARD® sales grew 13%, driven by major US orders

Full-year revenue grew 4% at constant exchange rates, stable gross margin at 65%

Company transitioned to IFRS for enhanced comparability and transparency

Outlook

Company expects strong start in 2026 with robust order book and lower cost base

SenzaGen sees UK animal testing phase-out benefiting its GARD® platform

Result Drivers

GARD® SALES GROWTH - Record-high Q4 GARD® sales with 13% growth, driven by major US orders

COST DISCIPLINE - Continued cost discipline contributed to a lower cost base despite negative FX effects

EXPANDED LABORATORIES - Expanded and more efficient laboratory facilities opened to increase capacity

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
SEK 58 mln
FY EPS
-SEK 0.39


Analyst Coverage

Wall Street's median 12-month price target for SenzaGen AB is SEK13.00, about 118.9% above its February 12 closing price of SEK5.94

Press Release: ID:nMFN5rplsP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)